You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
南韩增355宗确诊 并接报逾152宗注射疫苗後不良反应个案
阿思达克 03-01 16:23
南韩公布,至1日凌晨,新增355宗确诊新冠肺炎,其中338宗属本地感染个案,累计增至超9万宗。死亡个案增2宗,至1605宗。

韩国中央防疫对策本部表示,自上月26日开启新冠疫苗接种以来,共接到152起接种後出现异常反应的报告,均为轻微的机体反应,没有出现较为严重的过敏反应。其中151例与阿斯利康疫苗有关,1例与辉瑞疫苗有关。目前累计接种2.12万人。

152例不良反应中,有76%有出现发热,即超过38度以上;25%人出现肌肉酸痛、14%人出现头痛、11%人出现恶心及呕吐、10%出现发冷、9%人出现头晕和发疹。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account